查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1862512

噬菌體療法：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Phage Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024年全球噬菌體療法市場規模估計為 5,525萬美元，預計到2031年將達到 1.89億美元，在預測期（2025-2031年）內以 19.3%的年複合成長率成長。

噬菌體（正式名稱為細菌噬菌體）是一類能夠選擇性地標靶並殺死細菌的病毒。它們是自然界中分佈最廣泛的生物實體，已被證實能夠有效對抗並摧毀多重抗藥性細菌。也就是說，即使所有抗生素都已失效，噬菌體仍然可以成功殺死細菌，有可能挽救感染疾病。噬菌體不僅在人類醫學領域，在牙科、獸醫學和農業等領域也具有許多潛在的應用價值。

由於抗生素抗藥性感染疾病的增加、對新型治療方法的研究和開發活性化，以及市場參與者擴大採用收購和合作等成長策略，噬菌體市場預計將迎來顯著成長。

噬菌體是一類能夠附著在細菌上的病毒，它們會感染並最終摧毀宿主細胞。這些微生物透過自然過程破壞宿主細胞，而無需與人類或動物細胞直接接觸。噬菌體的應用在禽類和水產養殖領域尤其重要。儘管在現代醫學中，噬菌體在人類中的應用仍然很少見，但它們在畜牧、家禽和水產養殖中的應用已經取得了積極的成果。

全球噬菌體領域的主要公司包括NPO Microgen、Qingdao Phagepharm Bio-tech、Armata Pharmaceuticals, Inc.、Phaxiam Therapeutics、Eliava BioPreparations、Intralytix、MicroMir、Phagelux、Pharmex Group, LLC。截至2024年，全球前五大供應商約佔48%的營收佔有率。

本報告目的是依地區/國家、類型和應用對全球噬菌體療法市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名。

本報告以銷售收入為指標，對噬菌體療法市場規模、估算和預測進行了呈現，以2024年為基準年，並包含了2020年至2031年的歷史資料和預測資料。報告運用定量和定性分析，幫助讀者制定業務/成長策略，評估市場競爭格局，分析公司在當前市場中的地位，並就噬菌體療法做出明智的商業決策。

市場區隔

公司

  • NPO Microgen
  • Qingdao Phagepharm Bio-tech
  • Armata Pharmaceuticals, Inc.
  • Phaxiam Therapeutics
  • Eliava BioPreparations
  • Intralytix
  • MicroMir
  • Phagelux
  • Pharmex Group, LLC
  • APS Biocontrol Ltd.（APS）
  • ACD Pharma
  • Proteon Pharmaceuticals
  • Micreos
  • Locus Biosciences, Inc
  • NexaBiome Limited
  • PhagePro
  • BiomX
  • INtODEWORLD, Inc.
  • TechnoPhage
  • PhageLab
  • SciPhage
  • Kinzbio

依類型

  • 雙鏈DNA噬菌體
  • 單股DNA噬菌體
  • 單股RNA噬菌體
  • 其他

依應用

  • 人類健康
  • 動物健康
  • 水產養殖
  • 農業
  • 食品工業
  • 其他

依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Phage Therapy was estimated to be worth US$ 55.25 million in 2024 and is forecast to a readjusted size of US$ 189 million by 2031 with a CAGR of 19.3% during the forecast period 2025-2031.

Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature, and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection. phage has many potential applications in human medicine as well as dentistry, veterinary science, and agriculture.

The Bacteriophage market is expected to grow at a significant rate owing to rising prevalence of antibiotic resistant infection, rising research activities for and development of novel therapies, increasing adoption of growth strategies such as acquisitions, and collaborations by market players.

Bacteriophage is a type of virus that attaches itself to a bacterium and infects the host cell, subsequently destroying it. These microorganisms destroy their host cells through a natural process without interacting with human or animal cells. One of the most important sectors where the use of bacteriophages has emerged as very important is the poultry and aquaculture. While the use of bacteriophages in humans is still a rarity in modern medicine, their usage in animal husbandry, rearing poultry and fish is already showing positive results.

The major global companies of Bacteriophage include NPO Microgen, Qingdao Phagepharm Bio-tech, Armata Pharmaceuticals, Inc., Phaxiam Therapeutics, Eliava BioPreparations, Intralytix, MicroMir, Phagelux, and Pharmex Group, LLC, etc. In 2024, the world's top five vendors accounted for approximately 48% of the revenue.

This report aims to provide a comprehensive presentation of the global market for Phage Therapy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Phage Therapy by region & country, by Type, and by Application.

The Phage Therapy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Phage Therapy.

Market Segmentation

By Company

  • NPO Microgen
  • Qingdao Phagepharm Bio-tech
  • Armata Pharmaceuticals, Inc.
  • Phaxiam Therapeutics
  • Eliava BioPreparations
  • Intralytix
  • MicroMir
  • Phagelux
  • Pharmex Group, LLC
  • APS Biocontrol Ltd. (APS)
  • ACD Pharma
  • Proteon Pharmaceuticals
  • Micreos
  • Locus Biosciences, Inc
  • NexaBiome Limited
  • PhagePro
  • BiomX
  • INtODEWORLD, Inc.
  • TechnoPhage
  • PhageLab
  • SciPhage
  • Kinzbio

Segment by Type

  • DsDNA Bacteriophage
  • SsDNA Bacteriophage
  • SsRNA Bacteriophage
  • Others

Segment by Application

  • Human Health
  • Animal Health
  • Aquaculture
  • Agriculture
  • Food Industry
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Phage Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Phage Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Phage Therapy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Phage Therapy Product Introduction
  • 1.2 Global Phage Therapy Market Size Forecast (2020-2031)
  • 1.3 Phage Therapy Market Trends & Drivers
    • 1.3.1 Phage Therapy Industry Trends
    • 1.3.2 Phage Therapy Market Drivers & Opportunity
    • 1.3.3 Phage Therapy Market Challenges
    • 1.3.4 Phage Therapy Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Phage Therapy Players Revenue Ranking (2024)
  • 2.2 Global Phage Therapy Revenue by Company (2020-2025)
  • 2.3 Key Companies Phage Therapy Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Phage Therapy Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Phage Therapy
  • 2.6 Phage Therapy Market Competitive Analysis
    • 2.6.1 Phage Therapy Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Phage Therapy Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Phage Therapy as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 DsDNA Bacteriophage
    • 3.1.2 SsDNA Bacteriophage
    • 3.1.3 SsRNA Bacteriophage
    • 3.1.4 Others
  • 3.2 Global Phage Therapy Sales Value by Type
    • 3.2.1 Global Phage Therapy Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Phage Therapy Sales Value, by Type (2020-2031)
    • 3.2.3 Global Phage Therapy Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Human Health
    • 4.1.2 Animal Health
    • 4.1.3 Aquaculture
    • 4.1.4 Agriculture
    • 4.1.5 Food Industry
    • 4.1.6 Others
  • 4.2 Global Phage Therapy Sales Value by Application
    • 4.2.1 Global Phage Therapy Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Phage Therapy Sales Value, by Application (2020-2031)
    • 4.2.3 Global Phage Therapy Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Phage Therapy Sales Value by Region
    • 5.1.1 Global Phage Therapy Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Phage Therapy Sales Value by Region (2020-2025)
    • 5.1.3 Global Phage Therapy Sales Value by Region (2026-2031)
    • 5.1.4 Global Phage Therapy Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Phage Therapy Sales Value, 2020-2031
    • 5.2.2 North America Phage Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Phage Therapy Sales Value, 2020-2031
    • 5.3.2 Europe Phage Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Phage Therapy Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Phage Therapy Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Phage Therapy Sales Value, 2020-2031
    • 5.5.2 South America Phage Therapy Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Phage Therapy Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Phage Therapy Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Phage Therapy Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Phage Therapy Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Phage Therapy Sales Value, 2020-2031
    • 6.3.2 United States Phage Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Phage Therapy Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Phage Therapy Sales Value, 2020-2031
    • 6.4.2 Europe Phage Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Phage Therapy Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Phage Therapy Sales Value, 2020-2031
    • 6.5.2 China Phage Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Phage Therapy Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Phage Therapy Sales Value, 2020-2031
    • 6.6.2 Japan Phage Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Phage Therapy Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Phage Therapy Sales Value, 2020-2031
    • 6.7.2 South Korea Phage Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Phage Therapy Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Phage Therapy Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Phage Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Phage Therapy Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Phage Therapy Sales Value, 2020-2031
    • 6.9.2 India Phage Therapy Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Phage Therapy Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 NPO Microgen
    • 7.1.1 NPO Microgen Profile
    • 7.1.2 NPO Microgen Main Business
    • 7.1.3 NPO Microgen Phage Therapy Products, Services and Solutions
    • 7.1.4 NPO Microgen Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.1.5 NPO Microgen Recent Developments
  • 7.2 Qingdao Phagepharm Bio-tech
    • 7.2.1 Qingdao Phagepharm Bio-tech Profile
    • 7.2.2 Qingdao Phagepharm Bio-tech Main Business
    • 7.2.3 Qingdao Phagepharm Bio-tech Phage Therapy Products, Services and Solutions
    • 7.2.4 Qingdao Phagepharm Bio-tech Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Qingdao Phagepharm Bio-tech Recent Developments
  • 7.3 Armata Pharmaceuticals, Inc.
    • 7.3.1 Armata Pharmaceuticals, Inc. Profile
    • 7.3.2 Armata Pharmaceuticals, Inc. Main Business
    • 7.3.3 Armata Pharmaceuticals, Inc. Phage Therapy Products, Services and Solutions
    • 7.3.4 Armata Pharmaceuticals, Inc. Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Armata Pharmaceuticals, Inc. Recent Developments
  • 7.4 Phaxiam Therapeutics
    • 7.4.1 Phaxiam Therapeutics Profile
    • 7.4.2 Phaxiam Therapeutics Main Business
    • 7.4.3 Phaxiam Therapeutics Phage Therapy Products, Services and Solutions
    • 7.4.4 Phaxiam Therapeutics Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Phaxiam Therapeutics Recent Developments
  • 7.5 Eliava BioPreparations
    • 7.5.1 Eliava BioPreparations Profile
    • 7.5.2 Eliava BioPreparations Main Business
    • 7.5.3 Eliava BioPreparations Phage Therapy Products, Services and Solutions
    • 7.5.4 Eliava BioPreparations Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Eliava BioPreparations Recent Developments
  • 7.6 Intralytix
    • 7.6.1 Intralytix Profile
    • 7.6.2 Intralytix Main Business
    • 7.6.3 Intralytix Phage Therapy Products, Services and Solutions
    • 7.6.4 Intralytix Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Intralytix Recent Developments
  • 7.7 MicroMir
    • 7.7.1 MicroMir Profile
    • 7.7.2 MicroMir Main Business
    • 7.7.3 MicroMir Phage Therapy Products, Services and Solutions
    • 7.7.4 MicroMir Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.7.5 MicroMir Recent Developments
  • 7.8 Phagelux
    • 7.8.1 Phagelux Profile
    • 7.8.2 Phagelux Main Business
    • 7.8.3 Phagelux Phage Therapy Products, Services and Solutions
    • 7.8.4 Phagelux Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Phagelux Recent Developments
  • 7.9 Pharmex Group, LLC
    • 7.9.1 Pharmex Group, LLC Profile
    • 7.9.2 Pharmex Group, LLC Main Business
    • 7.9.3 Pharmex Group, LLC Phage Therapy Products, Services and Solutions
    • 7.9.4 Pharmex Group, LLC Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Pharmex Group, LLC Recent Developments
  • 7.10 APS Biocontrol Ltd. (APS)
    • 7.10.1 APS Biocontrol Ltd. (APS) Profile
    • 7.10.2 APS Biocontrol Ltd. (APS) Main Business
    • 7.10.3 APS Biocontrol Ltd. (APS) Phage Therapy Products, Services and Solutions
    • 7.10.4 APS Biocontrol Ltd. (APS) Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.10.5 APS Biocontrol Ltd. (APS) Recent Developments
  • 7.11 ACD Pharma
    • 7.11.1 ACD Pharma Profile
    • 7.11.2 ACD Pharma Main Business
    • 7.11.3 ACD Pharma Phage Therapy Products, Services and Solutions
    • 7.11.4 ACD Pharma Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.11.5 ACD Pharma Recent Developments
  • 7.12 Proteon Pharmaceuticals
    • 7.12.1 Proteon Pharmaceuticals Profile
    • 7.12.2 Proteon Pharmaceuticals Main Business
    • 7.12.3 Proteon Pharmaceuticals Phage Therapy Products, Services and Solutions
    • 7.12.4 Proteon Pharmaceuticals Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Proteon Pharmaceuticals Recent Developments
  • 7.13 Micreos
    • 7.13.1 Micreos Profile
    • 7.13.2 Micreos Main Business
    • 7.13.3 Micreos Phage Therapy Products, Services and Solutions
    • 7.13.4 Micreos Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.13.5 Micreos Recent Developments
  • 7.14 Locus Biosciences, Inc
    • 7.14.1 Locus Biosciences, Inc Profile
    • 7.14.2 Locus Biosciences, Inc Main Business
    • 7.14.3 Locus Biosciences, Inc Phage Therapy Products, Services and Solutions
    • 7.14.4 Locus Biosciences, Inc Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Locus Biosciences, Inc Recent Developments
  • 7.15 NexaBiome Limited
    • 7.15.1 NexaBiome Limited Profile
    • 7.15.2 NexaBiome Limited Main Business
    • 7.15.3 NexaBiome Limited Phage Therapy Products, Services and Solutions
    • 7.15.4 NexaBiome Limited Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.15.5 NexaBiome Limited Recent Developments
  • 7.16 PhagePro
    • 7.16.1 PhagePro Profile
    • 7.16.2 PhagePro Main Business
    • 7.16.3 PhagePro Phage Therapy Products, Services and Solutions
    • 7.16.4 PhagePro Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.16.5 PhagePro Recent Developments
  • 7.17 BiomX
    • 7.17.1 BiomX Profile
    • 7.17.2 BiomX Main Business
    • 7.17.3 BiomX Phage Therapy Products, Services and Solutions
    • 7.17.4 BiomX Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.17.5 BiomX Recent Developments
  • 7.18 INtODEWORLD, Inc.
    • 7.18.1 INtODEWORLD, Inc. Profile
    • 7.18.2 INtODEWORLD, Inc. Main Business
    • 7.18.3 INtODEWORLD, Inc. Phage Therapy Products, Services and Solutions
    • 7.18.4 INtODEWORLD, Inc. Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.18.5 INtODEWORLD, Inc. Recent Developments
  • 7.19 TechnoPhage
    • 7.19.1 TechnoPhage Profile
    • 7.19.2 TechnoPhage Main Business
    • 7.19.3 TechnoPhage Phage Therapy Products, Services and Solutions
    • 7.19.4 TechnoPhage Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.19.5 TechnoPhage Recent Developments
  • 7.20 PhageLab
    • 7.20.1 PhageLab Profile
    • 7.20.2 PhageLab Main Business
    • 7.20.3 PhageLab Phage Therapy Products, Services and Solutions
    • 7.20.4 PhageLab Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.20.5 PhageLab Recent Developments
  • 7.21 SciPhage
    • 7.21.1 SciPhage Profile
    • 7.21.2 SciPhage Main Business
    • 7.21.3 SciPhage Phage Therapy Products, Services and Solutions
    • 7.21.4 SciPhage Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.21.5 SciPhage Recent Developments
  • 7.22 Kinzbio
    • 7.22.1 Kinzbio Profile
    • 7.22.2 Kinzbio Main Business
    • 7.22.3 Kinzbio Phage Therapy Products, Services and Solutions
    • 7.22.4 Kinzbio Phage Therapy Revenue (US$ Million) & (2020-2025)
    • 7.22.5 Kinzbio Recent Developments

8 Industry Chain Analysis

  • 8.1 Phage Therapy Industrial Chain
  • 8.2 Phage Therapy Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Phage Therapy Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Phage Therapy Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Phage Therapy Market Trends
  • Table 2. Phage Therapy Market Drivers & Opportunity
  • Table 3. Phage Therapy Market Challenges
  • Table 4. Phage Therapy Market Restraints
  • Table 5. Global Phage Therapy Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Phage Therapy Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Phage Therapy Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Phage Therapy Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Phage Therapy
  • Table 10. Global Phage Therapy Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Phage Therapy as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Phage Therapy Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Phage Therapy Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Phage Therapy Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Phage Therapy Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Phage Therapy Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Phage Therapy Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Phage Therapy Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Phage Therapy Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Phage Therapy Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Phage Therapy Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Phage Therapy Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Phage Therapy Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Phage Therapy Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Phage Therapy Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Phage Therapy Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Phage Therapy Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Phage Therapy Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Phage Therapy Sales Value, (2026-2031) & (US$ Million)
  • Table 31. NPO Microgen Basic Information List
  • Table 32. NPO Microgen Description and Business Overview
  • Table 33. NPO Microgen Phage Therapy Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Phage Therapy Business of NPO Microgen (2020-2025)
  • Table 35. NPO Microgen Recent Developments
  • Table 36. Qingdao Phagepharm Bio-tech Basic Information List
  • Table 37. Qingdao Phagepharm Bio-tech Description and Business Overview
  • Table 38. Qingdao Phagepharm Bio-tech Phage Therapy Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Phage Therapy Business of Qingdao Phagepharm Bio-tech (2020-2025)
  • Table 40. Qingdao Phagepharm Bio-tech Recent Developments
  • Table 41. Armata Pharmaceuticals, Inc. Basic Information List
  • Table 42. Armata Pharmaceuticals, Inc. Description and Business Overview
  • Table 43. Armata Pharmaceuticals, Inc. Phage Therapy Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Phage Therapy Business of Armata Pharmaceuticals, Inc. (2020-2025)
  • Table 45. Armata Pharmaceuticals, Inc. Recent Developments
  • Table 46. Phaxiam Therapeutics Basic Information List
  • Table 47. Phaxiam Therapeutics Description and Business Overview
  • Table 48. Phaxiam Therapeutics Phage Therapy Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Phage Therapy Business of Phaxiam Therapeutics (2020-2025)
  • Table 50. Phaxiam Therapeutics Recent Developments
  • Table 51. Eliava BioPreparations Basic Information List
  • Table 52. Eliava BioPreparations Description and Business Overview
  • Table 53. Eliava BioPreparations Phage Therapy Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Phage Therapy Business of Eliava BioPreparations (2020-2025)
  • Table 55. Eliava BioPreparations Recent Developments
  • Table 56. Intralytix Basic Information List
  • Table 57. Intralytix Description and Business Overview
  • Table 58. Intralytix Phage Therapy Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Phage Therapy Business of Intralytix (2020-2025)
  • Table 60. Intralytix Recent Developments
  • Table 61. MicroMir Basic Information List
  • Table 62. MicroMir Description and Business Overview
  • Table 63. MicroMir Phage Therapy Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Phage Therapy Business of MicroMir (2020-2025)
  • Table 65. MicroMir Recent Developments
  • Table 66. Phagelux Basic Information List
  • Table 67. Phagelux Description and Business Overview
  • Table 68. Phagelux Phage Therapy Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Phage Therapy Business of Phagelux (2020-2025)
  • Table 70. Phagelux Recent Developments
  • Table 71. Pharmex Group, LLC Basic Information List
  • Table 72. Pharmex Group, LLC Description and Business Overview
  • Table 73. Pharmex Group, LLC Phage Therapy Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Phage Therapy Business of Pharmex Group, LLC (2020-2025)
  • Table 75. Pharmex Group, LLC Recent Developments
  • Table 76. APS Biocontrol Ltd. (APS) Basic Information List
  • Table 77. APS Biocontrol Ltd. (APS) Description and Business Overview
  • Table 78. APS Biocontrol Ltd. (APS) Phage Therapy Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Phage Therapy Business of APS Biocontrol Ltd. (APS) (2020-2025)
  • Table 80. APS Biocontrol Ltd. (APS) Recent Developments
  • Table 81. ACD Pharma Basic Information List
  • Table 82. ACD Pharma Description and Business Overview
  • Table 83. ACD Pharma Phage Therapy Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Phage Therapy Business of ACD Pharma (2020-2025)
  • Table 85. ACD Pharma Recent Developments
  • Table 86. Proteon Pharmaceuticals Basic Information List
  • Table 87. Proteon Pharmaceuticals Description and Business Overview
  • Table 88. Proteon Pharmaceuticals Phage Therapy Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Phage Therapy Business of Proteon Pharmaceuticals (2020-2025)
  • Table 90. Proteon Pharmaceuticals Recent Developments
  • Table 91. Micreos Basic Information List
  • Table 92. Micreos Description and Business Overview
  • Table 93. Micreos Phage Therapy Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Phage Therapy Business of Micreos (2020-2025)
  • Table 95. Micreos Recent Developments
  • Table 96. Locus Biosciences, Inc Basic Information List
  • Table 97. Locus Biosciences, Inc Description and Business Overview
  • Table 98. Locus Biosciences, Inc Phage Therapy Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Phage Therapy Business of Locus Biosciences, Inc (2020-2025)
  • Table 100. Locus Biosciences, Inc Recent Developments
  • Table 101. NexaBiome Limited Basic Information List
  • Table 102. NexaBiome Limited Description and Business Overview
  • Table 103. NexaBiome Limited Phage Therapy Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Phage Therapy Business of NexaBiome Limited (2020-2025)
  • Table 105. NexaBiome Limited Recent Developments
  • Table 106. PhagePro Basic Information List
  • Table 107. PhagePro Description and Business Overview
  • Table 108. PhagePro Phage Therapy Products, Services and Solutions
  • Table 109. Revenue (US$ Million) in Phage Therapy Business of PhagePro (2020-2025)
  • Table 110. PhagePro Recent Developments
  • Table 111. BiomX Basic Information List
  • Table 112. BiomX Description and Business Overview
  • Table 113. BiomX Phage Therapy Products, Services and Solutions
  • Table 114. Revenue (US$ Million) in Phage Therapy Business of BiomX (2020-2025)
  • Table 115. BiomX Recent Developments
  • Table 116. INtODEWORLD, Inc. Basic Information List
  • Table 117. INtODEWORLD, Inc. Description and Business Overview
  • Table 118. INtODEWORLD, Inc. Phage Therapy Products, Services and Solutions
  • Table 119. Revenue (US$ Million) in Phage Therapy Business of INtODEWORLD, Inc. (2020-2025)
  • Table 120. INtODEWORLD, Inc. Recent Developments
  • Table 121. TechnoPhage Basic Information List
  • Table 122. TechnoPhage Description and Business Overview
  • Table 123. TechnoPhage Phage Therapy Products, Services and Solutions
  • Table 124. Revenue (US$ Million) in Phage Therapy Business of TechnoPhage (2020-2025)
  • Table 125. TechnoPhage Recent Developments
  • Table 126. PhageLab Basic Information List
  • Table 127. PhageLab Description and Business Overview
  • Table 128. PhageLab Phage Therapy Products, Services and Solutions
  • Table 129. Revenue (US$ Million) in Phage Therapy Business of PhageLab (2020-2025)
  • Table 130. PhageLab Recent Developments
  • Table 131. SciPhage Basic Information List
  • Table 132. SciPhage Description and Business Overview
  • Table 133. SciPhage Phage Therapy Products, Services and Solutions
  • Table 134. Revenue (US$ Million) in Phage Therapy Business of SciPhage (2020-2025)
  • Table 135. SciPhage Recent Developments
  • Table 136. Kinzbio Basic Information List
  • Table 137. Kinzbio Description and Business Overview
  • Table 138. Kinzbio Phage Therapy Products, Services and Solutions
  • Table 139. Revenue (US$ Million) in Phage Therapy Business of Kinzbio (2020-2025)
  • Table 140. Kinzbio Recent Developments
  • Table 141. Key Raw Materials Lists
  • Table 142. Raw Materials Key Suppliers Lists
  • Table 143. Phage Therapy Downstream Customers
  • Table 144. Phage Therapy Distributors List
  • Table 145. Research Programs/Design for This Report
  • Table 146. Key Data Information from Secondary Sources
  • Table 147. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Phage Therapy Product Picture
  • Figure 2. Global Phage Therapy Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Phage Therapy Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Phage Therapy Report Years Considered
  • Figure 5. Global Phage Therapy Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Phage Therapy Revenue in 2024
  • Figure 7. Phage Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. DsDNA Bacteriophage Picture
  • Figure 9. SsDNA Bacteriophage Picture
  • Figure 10. SsRNA Bacteriophage Picture
  • Figure 11. Others Picture
  • Figure 12. Global Phage Therapy Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 13. Global Phage Therapy Sales Value Market Share by Type, 2024 & 2031
  • Figure 14. Product Picture of Human Health
  • Figure 15. Product Picture of Animal Health
  • Figure 16. Product Picture of Aquaculture
  • Figure 17. Product Picture of Agriculture
  • Figure 18. Product Picture of Food Industry
  • Figure 19. Product Picture of Others
  • Figure 20. Global Phage Therapy Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 21. Global Phage Therapy Sales Value Market Share by Application, 2024 & 2031
  • Figure 22. North America Phage Therapy Sales Value (2020-2031) & (US$ Million)
  • Figure 23. North America Phage Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Europe Phage Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Europe Phage Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Asia Pacific Phage Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. Asia Pacific Phage Therapy Sales Value by Region (%), 2024 VS 2031
  • Figure 28. South America Phage Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. South America Phage Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Middle East & Africa Phage Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Middle East & Africa Phage Therapy Sales Value by Country (%), 2024 VS 2031
  • Figure 32. Key Countries/Regions Phage Therapy Sales Value (%), (2020-2031)
  • Figure 33. United States Phage Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. United States Phage Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 35. United States Phage Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 36. Europe Phage Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Europe Phage Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 38. Europe Phage Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 39. China Phage Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. China Phage Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 41. China Phage Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Japan Phage Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Japan Phage Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Japan Phage Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 45. South Korea Phage Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. South Korea Phage Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 47. South Korea Phage Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 48. Southeast Asia Phage Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. Southeast Asia Phage Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 50. Southeast Asia Phage Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 51. India Phage Therapy Sales Value, (2020-2031) & (US$ Million)
  • Figure 52. India Phage Therapy Sales Value by Type (%), 2024 VS 2031
  • Figure 53. India Phage Therapy Sales Value by Application (%), 2024 VS 2031
  • Figure 54. Phage Therapy Industrial Chain
  • Figure 55. Phage Therapy Manufacturing Cost Structure
  • Figure 56. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 57. Bottom-up and Top-down Approaches for This Report
  • Figure 58. Data Triangulation
  • Figure 59. Key Executives Interviewed